MEDICINE
1.ANATOMICAL DIAGNOSIS:
LIVER? CARDIAC? KIDNEY?
ETIOLOGICAL DIAGNOSIS - ?? NEPHROTIC SYNDROME SECONDARY TO THE
DIABETIC NEPHROPATHY OR CKD
2) REASONS FOR:
I) AZOTEMIA : IMPAIRED RENAL EXCRETION OF UREA AND CREATININE SECONDARY TO CKD.
II) ANEMIA : DECREASED ERYTHROPOIETIN
III) HYPOALBUNEMIA: CAPILLARY BASEMENT MEMBRANE AND PODOCYTES DAMAGE
IV) ACIDOSIS: ACIDIFICATION OF URINE LOST.
3. RATIONALE SYRUP. POTCHLOR WAS GIVEN BECAUSE OF HYPOKALEMIA.
INJ. BICARBONATE WAS GIVEN BECAUSE OF METABOLIC ACIDOSIS.
INSULIN AND HYPERTENSIVES ARE GIVEN BECAUSE KNOWN CASE OF DM AND HTN.
OROFER XT WAS GIVEN BECAUSE OF ANEMIA.
INJ.LASIX WAS GIVEN BECAUSE TO DECREASE HER VOLUME OVERLOAD.
SPIRONOLACTONE WAS GIVEN BECAUSE IT WAS A POTASSIUM SPARING DIURETIC.
CALCIUM WAS GIVEN TO THE PATIENT BECAUSE OF HYPOCALCEMIA SECONDARY TO CKD.
4. INDICATIONS OF DIALYSIS IN THIS PT :
WORSENING OF SOB SECONDARY TO METABOLIC ACIDOSIS WITH ANURIA NOT RESOLVED WITH HIGH CEILING DIURETICS
CRUCIAL FACTOR : PT BECAME SYMPTOMATIC ON 3RD DAY.
5. CAUSES OF SOME CONDITIONS
MINIMAL CHANGE DISEASE
FOCAL SEGMENTAL GLOMERULOSCLEROSIS
SECONDARY:
DIABETES MELLITUS
SLE
HIV INFECTION
AMYLOIDOSIS
SARCOIDOSIS
DRUGS:NSAIDS
CANCER;HODGKIN'S DISEASE
NON HODGKIN'S DISEASE
RCC LUNG
6. HIGH MORTALITY IS SEEN IN CKD WITH HYPO ALBUMINEMIA
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752034/
7.MACRO VASCULAR CHANGES ACCOMPANYING CKD, SUCH AS HYPERTENSION AND
ARTERIAL STIFFENING , HAVE BEEN DESCRIBED TO CONTRIBUTE TO HFpEF
DEVELOPMENT .FURTHERMORE, SEVERAL RENAL FACTORS HAVE A DIRECT IMPACT ON
THE HEART AND/OR CORONARY MICRO VASCULATURE AND MAY UNDERLIE THE
ASSOCIATION BETWEEN CKD AND HFpEF.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737277/
8. EFFICACY OF DRUGS OVER PLACEBO IN ANEMIA :117 PATIENTS RECEVIED ORAL
FERRIC CITRATE AND 115 PATEINTS RECEIVED PLACEBO FOR 16 WEEK RANDOMIZED
PERIOD . 52.1%PATIENTS RECEIVING FERRIC CITRATE ACHEIVED PRIMARY ENDPOINT OF
INCREASED HB LEVELS . COMPARING TO 19.1% PATIENTS RECEIVING PLACEBO. OVER
ALL PTS IN CKD , FOUND ORAL FERRIC CITRATE FOUND TO BE SAFE AND EFFICACIOUS
TREATMENT FOR IDA ANOTHER TRIAL :BETWEEN FERUMOXYTOL AND PLACEBO FOR
ANEMIA IN IDA AND GI DISORDERS VS PLACEBO IN PTS WHO FAILED OR WERE
INTOLERANT TO ORAL IRON THERAPHY
RESULTS:PTS WITH IDA RECEIVING FERUMOXYTOL RECEIVED A LEVELS OF >20G/DL IN
HB VS PLACEBO PTS
https://www.dovepress.com/ferumoxytol-versus-placebo-in-iron-deficiency-anemia-efficacy-safety-a-peer-reviewed-fulltext-article-CEG
9. ANEMIA CONTRIBUTES TO THE IMPAIRMENT OF HEALTH RELATED QUALITY OF LIFE
(HRQoL) IN PATIENTS WITH CKD . ITS IMPACT ON PATIENTS HRQoL BURDEN ITS
EXACERBATED BY REDUCED PHYSICAL CAPACITY AND ENERGY LEVELS AMONG OTHER
PATIENTS.
10. S. ALBUMIN: IT IS BELIEVED THAT PRINICIPAL NUTRITION MARKER USED TO
IDENTIFY
MALNUTRITION PATIENTS WITH CKD BUT ACCORDING TO MDRD STUDY RESTRICTED
DIETARY PROTIEN INTAKE TO AS LITTLE AS 0.56g/kg/day S.ALBUMIN REMAINED >4mg/dl
EVEN MORE SEVERE RESTRICTION OF DIETARY PROTIEN (0.3-0.49/kg/day) DIDNOT CAUSE
REDUCTION IN SERUM ALBUMIN
IF NO. OF OBSERVATIONAL STUDIES,INCLUDING THE ENROLLING HEMODIALYSIS
PTS,THE LOW S.ALBUMIN LEVELS IN DIALYSIS PATIENTS ARE A/W SYSTEMIC
INFLAMMATION WITH LITTLE EVIDENCE IMPLICATING INADEQUATE NUTRITION AS
CAUSATIVE FACTOR
IN SUMMARY A PLETHORA OF CORROBORATIVE CLINICAL EVIDENCE IN
GEN.POPULATION AND IN PATIENTS WITH CKD SHOWED S.ALBUMIN IS AN INSENSITIVE
INDICATION OF MALNUTRITION.
file:///Users/SHASHI/Downloads/SGA%20Tool%20EN%20colour_2017(1).pdf
11. 58M HAD HISTORY WITH COUGH AND ELEVATED TLC WITH INDICATES
ACUTE RENAL INJURY AND ALSO THERE IS NO ALBUMINURIA AND EDEMA
.WHERE AS IN 45 F HAD A PEDAL EDEMA , FACIAL PUFFINESS , ABDOMINAL
DISTENSION , ANURIA WHICH CLEARLY INDICATES NEPHROTIC NEPHRITIC
SYNDROME.. AND INVESTIGATIONS SHOWED THAT THERE IS
MICROALBUMINURIA , MICRO HAEMATURIA IN THIS PATIENT.
Comments
Post a Comment